Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 4(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03621215Not ApplicableTerminated

The Effect of Tart Cherry Juice on Risk of Gout Attacks

Role: collaborator

NCT02154100Phase 2Completed

Tart Cherry, Metabolic Syndrome, and Cardiovascular Risk

Role: collaborator

NCT01547949Phase 4Completed

Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults

Role: collaborator

NCT01073982Phase 4Completed

Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis

Role: collaborator

All 4 trials loaded